Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419-421

ArticleinScience 308(5720):419-21 · May 2005with35 Reads
Impact Factor: 33.61 · DOI: 10.1126/science.1110359 · Source: PubMed
Abstract

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the elderly whose etiology remains largely unknown. Previous studies identified chromosome 1q32 as harboring a susceptibility locus for AMD. We used single-nucleotide polymorphisms to interrogate this region and identified a strongly associated haplotype in two independent data sets. DNA resequencing of the complement factor H gene within this haplotype revealed a common coding variant, Y402H, that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57. This common variant likely explains approximately 43% of AMD in older adults.

Full-text

Available from: Anita Agarwal
16. D.E.Angelaki,A.G.Shaikh,A.M.Green,J.D.Dickman,
Nature 430, 560 (2004).
17. W. O. Guldin, O. J. Grusser, Trends Neurosci. 21, 254
(1998).
18. Materials and methods are available as supporting
material on Science Online.
19. H. Imamizu et al., Nature 403, 192 (2000).
20. A mean visuomotor processing time of 171 ms was
estimated for both 1g and –1g trials, on the basis of
methods described in (4, 22).
21. Both the 1g model and the t model use on-line visual
information about target position and velocity to trig-
ger an interceptive movement when TTC(t)[see(14)]
reaches a time threshold equal to the visuomotor
processing time (22). However, the 1g model com-
putes T TC(t) under the assumption that the target is
accelerated by gravity [Eq. 1 in (14)], whereas the t
model assumes that the target moves at constant
speed [TTC(t) 0 h
ˆ
w
(t)=v
ˆ
w
(t), see (4, 23)]. Therefore, if
the brain uses the 1g model to predict target motion,
the responses to 1g trials will be correctly timed. By
contrast, the t model overestimates the TTC(t)of1g
trials and predicts that the corresponding responses
should be systematically late. As a quantitative test,
the time of response was computed separately for
the five flight durations and was averaged across all
trials of all subjects for a given flight duration. For
1g trials, the response times predicted by the 1g
model were highly correlated with the experimen-
tal values in all subjects (mean r 0 0.998), whereas
those predicted by the t model systematically failed
to fit the experimental values (mean r 0 0.5). The
root mean square error (RMSE) of the fit to 1g trials
wasworsebyafactorof1.7forthet model than
for the 1g model. For –1g trials, the response times
predicted by the t model were highly correlated
with the experimental values in all subjects (mean
r 0 0.973), and adequacy of the fit was demon-
strated by the random distribution of the residuals
around the mean over the data range. Instead, the
1g model fitted the responses to –1g trials less
adequately, as shown by a systematic bias of the
residuals around the mean (thus r value was not
computed for this fit). Accordingly, the RMSE of
the fit was 3.6 times worse for the 1g model than
for the t model.
22. M. Zago et al., J. Neurophysiol. 91, 1620 (2004).
23. D. N. Lee, P. E. Reddish, Nature 293, 293 (1981).
24. G. Bottini et al., Exp. Brain Res. 99, 164 (1994).
25. T.Brandt,M.Dieterich,A.Danek,Ann. Neurol. 35, 403
(1994).
26. R. J. Peterka, C. C. Gianna-Poulin, L. H. Zupan, D. M.
Merfeld, J. Neurophysiol. 92, 2333 (2004).
27. S. Bense, T. Stephan, T. A. Yousry, T. Brandt, M. Dieterich,
J. Neurophysiol. 85, 886 (2001).
28. G. A. Orban et al., Neuropsychologia 41, 1757 (2003).
29. G. Rees, K. Friston, C. Koch, Nat. Neurosci. 3, 716 (2000).
30. H. Merchant, A. Battaglia-Mayer, A. P. Georgopoulos,
Cereb. Cortex 14, 314 (2004).
31. O. J. Grusser, M. Pause, U. Schreiter, J. Physiol. 430, 537
(1990).
32. O. Blanke, S. Ortigue, T. Landis, M. Seeck, Nature 419,
269 (2002).
33. V. Smetacek, Nature 415, 481 (2002).
34. R. N. Shepard, Psychol. Rev. 91, 417 (1984).
35. L. H. Zupan, D. M. Merfeld, C. Darlot, Biol. Cybern.
86, 209 (2002).
36. We thank R. Frackowiak, C. D. Frith, G. Galati, C. Porro,
G. Rizzolatti, and J. N. Sanes for comments and advice
on previous versions of this work. Supported by the
Italian Ministry of Health, the Italian Ministry of Uni-
versity and Research (FIRB and PRIN grants), and the
Italian Space Agency.
Supporting Online Material
www.sciencemag.org/cgi/content/full/308/5720/416/
DC1
Materials and Methods
SOM Text
Fig. S1
Tables S1 to S5
References and Notes
Movie S1
29 November 2004; accepted 31 January 2005
10.1126/science.1107961
Complement Factor H Variant
Increases the Risk of Age-Related
Macular Degeneration
Jonathan L. Haines,
1
Michael A. Hauser,
2
Silke Schmidt,
2
William K. Scott,
2
Lana M. Olson,
1
Paul Gallins,
2
Kylee L. Spencer,
1
Shu Ying Kwan,
2
Maher Noureddine,
2
John R. Gilbert,
2
Nathalie Schnetz-Boutaud,
1
Anita Agarwal,
3
Eric A. Postel,
4
Margaret A. Pericak-Vance
2
*
Age-related macular degeneration (AMD) is a leading cause of visual impair-
ment and blindness in the elderly whose etiology remains largely unknown.
Previous studies identified chromosome 1q32 as harboring a susceptibility
locus for AMD. We used single-nucleotide polymorphisms to interrogate this
region and identified a strongly associated haplotype in two independent data
sets. DNA resequencing of the complement factor H gene within this haplo-
type revealed a common coding variant, Y402H, that significantly increases
the risk for AMD with odds ratios between 2.45 and 5.57. This common var-
iant likely explains È43% of AMD in older adults.
AMD causes progressive impairment of cen-
tral vision and is the leading cause of ir-
reversible vision loss in older Americans
(1). The most severe form of AMD involves
neovascular/exudative (wet) and/or atrophic
(dry) changes to the macula. Although the
etiology of AMD remains largely unknown,
implicated risk factors include age, ethnicity,
smoking, hypertension, obesity, and diet (2).
Familial aggregation (3), twin studies (4),
andsegregationanalysis(5) suggest that there
is also a substantial genetic contribution to
the disease. The candidate gene approach,
which focuses on testing biologically rele-
vant candidates, has implicated variants in
the ABCA4, FBLN6, and APOE genes as risk
factors for AMD. Replication of the ABCA4
and FBLN6 findings has been difficult, and
in toto these variants explain a small propor-
tion of AMD (6–8). The alternative genomic
approach uses a combination of genetic link-
age and association to identify previously
unknown genes involved in AMD. We par-
ticipated in a recent collaborative genomewide
linkage screen (9) in which chromosome 1q32
Table 1. CFH sequence variants identified in neovascular AMD cases and normal controls. All individuals
were homozygous for the AMD-associated GAGGT haplotype. The 24 affected individuals selected for
sequencing had severe neovascular disease (grade 5) (12) with diagnosis before age 74 (mean age at
diagnosis: 65.8 years). The 24 control individuals selected for sequencing had no evidence of AMD (grade
1) with age at exam after age 64 (mean age at exam: 69.8 years). The six previously identified SNPs are
labeled using standard nomenclature. The five previously unknown variants are labeled given their base
pair location on chromosome 1, Ensembl build 35. Five SNPs create nonsynonymous amino acid changes
within CFH, and five SNPs create synonymous changes. Exon 1 is not translated. n/a, not applicable.
Location SNP ID Effect
Minor allele frequency (%)
AMD Controls
Exon 1 rs3753394 n/a 18 24
Exon 2 rs800292 V62I 0 6
Exon 6 193,380,486 A/G R232R 0 2
Exon 7 rs1061147 A307A 10 38
Exon 8 193,390,164 C/T H332Y 0 5
Exon 9 rs1061170 Y402H 94 46
Exon 11 193,414,604 A/G A473A 0 31
Exon 12 193,416,415 A/G T519A 0 2
Exon 14 rs3753396 Q672Q 0 23
Exon 18 193,438,299 C/T H878H 6 2
Exon 19 HGVbase 000779895 E936D 0 23
1
Center for Human Genetics Research, Vanderbilt
University Medical Center, Nashville, TN 37232, USA.
2
Center for Human Genetics and Department of
Medicine, Duke University Medical Center, DUMC
Box 3445, 595 LaSalle Street, Durham, NC 27710,
USA.
3
Vanderbilt Eye Institute, Vanderbilt University
Medical Center, Nashville, TN 37232, USA.
4
Duke
University Eye Center and Department of Ophthal-
mology, Duke University Medical Center, Durham,
NC 27710, USA.
*To whom correspondence should be addressed.
E-mail: mpv@chg.duhs.duke.edu
R EPORTS
www.sciencemag.org SCIENCE VOL 308 15 APRIL 2005
419
Page 1
was identified as a likely region for an AMD
risk gene, a location also supported by other
studies (10, 11).
To identify the responsible gene on chro-
mosome 1q32, we initially genotyped 44
single nucleotide polymorphisms (SNPs) (12)
across the 24 megabases (Mb) incorporat-
ing this linkage region. We examined two
independent data sets: The first contained
182 families (111 multiplex and 71 discordant
sibpairs), and the second contained 495 AMD
cases and 185 controls. Each SNP was tested
for association independently in both data
sets. Two SNPs (rs2019724 and rs6428379)
in moderate linkage disequilibrium with each
other (r
2
0 0.61) generated highly signifi-
cant associations with AMD in both the
family-based data set (rs2019724, P 0 0.0001;
rs6428379, P 0 0.0007) and in the case-
control data set (rs2019724, P G 0.0001;
rs6428379, P G 0.0001). These SNPs lie È263
kilobases (kb) apart.
To completely define the extent of linkage
disequilibrium, we genotyped an additional 17
SNPs across È655 kb flanked by rs1538687
and rs1537319 and encompassing the 263-kb
region. Two linkage disequilibrium blocks of
11 and 74 kb were identified and were sep-
arated by 176 kb (Fig. 1). The 11-kb block
contained rs2019724, and the 74-kb block con-
tained rs6428379. Association analysis of the
17 SNPs identified multiple additional SNPs
giving highly significant associations in one or
both of the family-based and case-control data
sets (Fig. 2). In the case-control data set, a
five-SNP haplotype (GAGGT, defined by SNPs
rs1831281, rs3753395, rs1853883, rs10494745,
and rs6428279, respectively) constituted 46%
of the case and 33% of the control chromo-
somes (P 0 0.0003). This same haplotype was
also significantly overtransmitted to affected
individuals in the family-based data set (P 0
0.00003). The convergence of the most sig-
nificant associations to this same haplotype in
the two independent data sets strongly sug-
gests that this region contains a commonly
inherited variant in an AMD risk gene.
The associated GAGGT haplotype spans
È261 kb. It contains the Complement Factor
H gene (CFH, OMIM #134370, accession
#NM_000186) and the five Complement
Factor H–related genes CFHL1 to CFHL5,
and lies within the Regulator of Complement
Activation (RCA) gene cluster. The most
consistent association results (Fig. 2) from
both the family-based and case-control data
sets converge within the CFH gene, implicat-
ing CFH as the AMD susceptibility gene. The
biological role of Complement Factor H as a
component of the innate immune system that
modulates inflammation through regulation of
complement (13) enhances its attractiveness
as a candidate AMD susceptibility gene.
Inflammation has been repeatedly implicated
in AMD pathology. C-reactive protein levels
are elevated in advanced disease (14), anti-
retinal autoantibodies have been detected in
AMD patients (15), macrophages are localized
near neovascular lesions (16), and the hallmark
drusen deposits contain many complement-
related proteins (17).
We screened for potential risk-associated
sequence variants in the coding region of
CFH by sequencing 24 cases with severe
neovascular disease and 24 controls with no
evidence of AMD. To maximize the likeli-
hood of identifying the risk-associated allele,
all sequenced cases and controls were homo-
zygous for the GAGGT haplotype. Five
previously unknown and six known sequence
variants were detected (Table 1). Only one
variant (rs1061170, sequence: T1277C; pro-
tein: Y402H) was present significantly more
often in cases than controls, occurring on 45
of 48 haplotypes in the cases and on 22 of 48
Fig. 1. Haploview plot defining haplotype block structure of AMD-associated region. The relative
physical position of each SNP is given in the upper diagram, and the pairwise linkage
disequilibrium (D) between all SNPs is given below each SNP combination. Dark red–shaded
squares indicated D values 9 0.80. D 0 1.0 when no number is given.
Fig. 2. Plot of family-based and case-control P values for all SNPs within the AMD-associated
haplotype. The genomic region spanning each gene is indicated in green. jlog
10
of the nominal
P values are plotted for each SNP. Results for both the family-based and case-control data sets
converge within the CFH gene.
R EPORTS
15 APRIL 2005 VOL 308 SCIENCE www.sciencemag.org
420
Page 2
haplotypes in the controls (P G 0.0001). The
frequency of sequence variants within the
CFH coding region on the associated haplo-
type was significantly reduced in cases com-
pared to controls (12% versus 18%, P 0 0.002).
When the overrepresented T1277C variant
was removed from the analysis, this differ-
ence became more pronounced (3% versus
16%, P G 0.00001). Thus, T1277C is the pri-
mary DNA sequence variant differentiating
between the case and control haplotypes.
Complete genotyping of T1277C in the
family-based and case-control data sets re-
vealed a significant overtransmission in the
families (P 0 0.019) (12) and a highly sig-
nificant overrepresentation in the cases com-
pared to controls (P 0 0.00006). The odds
ratio for AMD was 2.45 E95% confidence
interval (CI): 1.41 to 4.25^ for carriers of one
C allele and 3.33 (95% CI: 1.79 to 6.20) for
carriers of two C alleles. When the analysis
was restricted to only neovascular AMD,
these odds ratios increased to 3.45 (95% CI:
1.72 to 6.92) and 5.57 (95% CI: 2.52 to
12.27), respectively. This apparent dose ef-
fect for risk associated with the C allele was
highly significant (P G 0.0001). There was
no apparent allelic or genotypic effect of
T1277C on age at AMD diagnosis (mean age
at diagnosis: TT, 76.5 years; TC, 77.5 years;
CC, 75.5 years). The population attributable
risk percent for carrying at least one C allele
was 43% (95% CI: 23 to 68%).
The Y402H variant is predicted to have
functional consequences consistent with AMD
pathology. Residue 402 is located within
binding sites for heparin (18) and C-reactive
protein (CRP) (19). Binding to either of these
partners increases the affinity of CFH for the
complement protein C3b (20, 21), augmenting
its ability to down-regulate complement_sef-
fect. The observed colocalization of CFH,
CRP, and proteoglycans in the superficial
layer of the arterial intima suggests that CFH
may protect the host arterial wall from excess
complement activation (22). We hypothesize
that allele-specific changes in the activities of
the binding sites for heparin and CRP would
alter CFH_s ability to suppress complement-
related damage to arterial walls and might ul-
timately lead to vessel injury and subsequent
neovascular/exudative changes such as those
seen in neovascular AMD. Our data support
this hypothesis, because the risk associated
with the C allele is more pronounced when
the analyses are restricted to neovascular
AMD. Given the known functional interac-
tions of genes within the RCA gene cluster
(13), variants within these genes could inter-
act with or modify the effect of the T1277C
variant.
Plasma levels of CFH are known to de-
crease with smoking (23), a known risk
factor for AMD (2). This confluence of
genetic and environmental risk factors sug-
gests an integrated etiological model of
AMD involving chronic inflammation. Iden-
tification of the increased risk of AMD
associated with the T1277C variant should
enhance our ability to develop presympto-
matic tests for AMD, possibly allowing
earlier detection and better treatment of this
debilitating disorder.
References and Notes
1. Centers for Disease Control and Prevention (CDC),
Morb. Mortal. Wkly. Rep. 53, 1069 (2004).
2. J. Ambati, B. K. Ambati, S. H. Yoo, S. Ianchulev, A. P.
Adamis, Surv. Ophthalmol. 48, 257 (2003).
3. C. C. Klaver et al., Arch. Ophthalmol. 116, 1646 (1998).
4. C. J. Hammond et al., Ophthalmology 109, 730
(2002).
5. I. M. Heiba, R. C. Elston, B. E. Klein, R. Klein, Genet.
Epidemiol. 11, 51 (1994).
6. E. M. Stone et al., Nat. Genet. 20, 328 (1998).
7. S. Schmidt et al., Ophthalmic Genet. 23, 209 (2002).
8. D. W. Schultz et al., Hum. Mol. Genet. 12, 3315
(2003).
9. D. E. Weeks et al., Am.J.Hum.Genet.75, 174
(2004).
10. G. R. Abecasis et al., Am.J.Hum.Genet.74, 482
(2004).
11. S. K. Iyengar et al., Am. J. Hum. Genet. 74, 20 (2004).
12. Materials and methods are available as supporting
material on Science Online.
13. S. Rodriguez de Cordoba, J. Esparza-Gordillo, E. Goicoechea
de Jorge, M. Lopez-Trascasa, P. Sanchez-Corral, Mol.
Immunol. 41, 355 (2004).
14. J. M. Seddon, G. Gensler, R. C. Milton, M. L. Klein,
N. Rifai, J.Am.Med.Assoc.291, 704 (2004).
15. D. H. Gurne, M. O. Tso, D. P. Edward, H. Ripps,
Ophthalmology 98, 602 (1991).
16. M. C. Killingsworth, J. P. Sarks, S. H. Sarks, Eye 4, 613
(1990).
17. R. F. Mullins, S. R. Russell, D. H. Anderson, G. S.
Hageman, FASEB J. 14, 835 (2000).
18. T. K. Blackmore, V. A. Fischetti, T. A. Sadlon, H. M.
Ward, D. L. Gordon, Infect. Immun. 66, 1427 (1998).
19. E. Giannakis et al., Eur. J. Immunol. 33, 962 (2003).
20. D. T. Fearon, Proc. Natl. Acad. Sci. U.S.A. 75, 1971
(1978).
21. C. Mold, M. Kingzette, H. Gewurz, J. Immunol. 133,
882 (1984).
22. R. Oksjoki et al., Arterioscler. Thromb. Vasc. Biol. 23,
630 (2003).
23. J. Esparza-Gordillo et al., Immunogenetics 56, 77 (2004).
24. We thank all of the study participants and their rela-
tives; M. de la Paz, M. Klein, J. Caldwell, R. Domurath,
K. Haynes, V. Mitchell, M. Shaw, and J. Galloway for
participant ascertainment; K. Abramson, J. Benton, W.
Lambert, B. Love, T. Skelly, E. Tegnell, M. Allen, C.
Haynes, R. Chung, and J. Bunch for valuable technical
assistance; J. M. Vance and M. Summar for critical
reading of the manuscript; and D. J. M. Gass for
patient ascertainment and clinical expertise. We also
thank the following clinics and clinicians for referring
individuals to the study: Southern Retina, L.L.C (C. Harris);
Vitreo-Retinal Surgeons (M. Duan and C. Devine); Georgia
Retina, P.C.; and The Retina Group of Washington.
Supported by grants EY12118 (to M.A.P.-V. and J.L.H.)
and EY015216 (to S.S.) from the NIH/National Eye
Institute, grant AG11268 from the NIH/National Institute
on Aging (to H. Cohen), and grant M01 RR-00095 from
the NIH/National Center for Research Resources (to
Vanderbilt University).
Supporting Online Material
www.sciencemag.org/cgi/content/full/1110359/DC1
Materials and Methods
Table S1
References
28 January 2005; accepted 23 February 2005
Published online 10 March 2005;
10.1126/science.1110359
Include this information when citing this paper
Complement Factor H
Polymorphism and Age-Related
Macular Degeneration
Albert O. Edwards,
1
*
. Robert Ritter III,
1
Kenneth J. Abel,
2
Alisa Manning,
3
Carolien Panhuysen,
3,6
Lindsay A. Farrer
3,4,5,6,7
Age-related macular degeneration (AMD) is a common, late-onset, and com-
plex trait with multiple risk factors. Concentrating on a region harboring a
locus for AMD on 1q25-31, the ARMD1 locus, we tested single-nucleotide
polymorphisms for association with AMD in two independent case-control
populations. Significant association (P 0 4.95 10
j10
) was identified
within the regulation of complement activation locus and was centered
over a tyrosine-402 Y histidine-402 protein polymorphism in the gene en-
coding complement factor H. Possession of at least one histidine at amino
acid position 402 increased the risk of AMD 2.7-fold and may account for
50% of the attributable risk of AMD.
AMD is a leading cause of blindness in older
individuals (1). It is a late-onset, complex
trait with hereditary, lifestyle, and medical
risk factors (2). The condition typically pre-
sents in the fifth decade of life with small
yellow deposits external to the outer retina
and retinal pigment epithelium (RPE) called
drusen. Large numbers of drusen and clini-
cal features of damage to the RPE markedly
increase the risk of complications (atrophy
of the RPE and abnormal neovasculariza-
tion of the outer retina), leading to severe
vision loss (1).
Although the primary pathogenic mecha-
nisms of AMD were previously unknown,
there is strong evidence that genetics plays a
role (3–9). The first locus for AMD (ARMD1)
was reported in a single extended family linked
to chromosome 1q25.3-31.3 (5). Because there
was strong evidence for linkage to this region
R EPORTS
www.sciencemag.org SCIENCE VOL 308 15 APRIL 2005
421
Page 3
    • "CFH CFH is the primary inhibitor of the alternative complement pathway. Genetic studies identified strong associations between AMD and a coding variant (Tyr402His; rs1061170) and several noncoding variants in the CFH gene (Edwards et al. 2005; Hageman et al. 2005; Haines et al. 2005). In addition to these common genetic variants , rare variants with an even larger effect have been identified in the CFH gene (Fig. 2A). "
    [Show abstract] [Hide abstract] ABSTRACT: Age-related macular degeneration (AMD) is a complex disease caused by a combination of genetic and environmental factors. Genome-wide association studies have identified several common genetic variants associated with AMD, which together account for 15%-65% of the heritability of AMD. Multiple hypotheses to clarify the unexplained portion of genetic variance have been proposed, such as gene-gene interactions, gene-environment interactions, structural variations, epigenetics, and rare variants. Several studies support a role for rare variants with large effect sizes in the pathogenesis of AMD. In this work, we review the methods that can be used to detect rare variants in common diseases, as well as the recent progress that has been made in the identification of rare variants in AMD. In addition, the relevance of these rare variants for diagnosis, prognosis, and treatment of AMD is highlighted.
    Full-text · Article · Nov 2014 · Cold Spring Harbor Perspectives in Medicine
    0Comments 2Citations
    • "Homeostatic disturbances, when uncompensated, lead to sustained oxidative stress and compromised mitochondrial function, resulting in apoptotic cell death (Bazan 2007; de Jong 2006; Dunaief et al. 2002; Feher et al. 2006; Lukiw et al. 2005; Mendes et al. 2005; Sreekumar et al. 2005; Takahashi et al. 2004). Single nucleotide polymorphisms (SNPs) occurring in complement factor H gene (CFH/HF1) (Edwards et al. 2005; Hageman et al. 2005; Haines et al. 2005; Klein et al. 2005) are a major risk factor for developing AMD. CFH is an inhibitor of the alternative pathway of complement system activation that limits complement-induced cell injury and inflammation (Bok 2005; Gold et al. 2006). "
    [Show abstract] [Hide abstract] ABSTRACT: Docosahexaenoic acid (DHA), an omega-3 fatty acid family member, is obtained by diet or synthesized from dietary essential omega-3 linolenic acid and delivered systemically to the choriocapillaris, from where it is taken up by the retinal pigment epithelium (RPE). DHA is then transported to the inner segments of photoreceptors, where it is incorporated in phospholipids during the biogenesis of outer segment disk and plasma membranes. As apical photoreceptor disks are gradually shed and phagocytized by the RPE, DHA is retrieved and recycled back to photoreceptor inner segments for reassembly into new disks. Under uncompensated oxidative stress, the docosanoid neuroprotectin D1 (NPD1), a potent mediator derived from DHA, is formed by the RPE and displays its bioactivity in an autocrine and paracrine fashion. The purpose of this study was to determine whether photoreceptors have the ability to synthesize NPD1, and whether or not this lipid mediator exerts bioactivity on these cells. For this purpose, 661W cells (mouse-derived photoreceptor cells) were used. First we asked whether these cells have the ability to form NPD1 by incubating cells with deuterium (d4)-labeled DHA exposed to dark and bright light treatments, followed by LC-MS/MS-based lipidomic analysis to identify and quantify d4-NPD1. The second question pertains to the potential bioactivity of these lipids. Therefore, cells were incubated with 9-cis-retinal in the presence of bright light that triggers cell damage and death. Following 9-cis-retinal loading, DHA, NPD1, or vehicle were added to the media and the 661W cells maintained either in darkness or under bright light. DHA and NPD1 were then quantified in cells and media. Regardless of lighting conditions, 661W cells acquired DHA from the media and synthesized 4-9 times as much d4-NPD1 under bright light treatment in the absence and presence of 9-cis-retinal compared to cells in darkness. Viability assays of 9-cis-retinal-treated cells demonstrated that 34 % of the cells survived without DHA or NPD1. However, after bright light exposure, DHA protected 23 % above control levels and NPD1 increased protection by 32 %. In conclusion, the photoreceptor cell line 661W has the capability to synthesize NPD1 from DHA when under stress, and, in turn, can be protected from stress-induced apoptosis by DHA or NPD1, indicating that photoreceptors effectively contribute to endogenous protective signaling mediated by NPD1 under stressful conditions.
    Full-text · Article · Sep 2014 · Cellular and Molecular Neurobiology
    0Comments 6Citations
    • "Thus, the expression of certain genes may reveal both protective and detrimental characteristics, depending on the phase of the disease (see Table 1). Following the discovery that retinal drusen contain CSrelated proteins, several reports appeared in 2005 and stated that the chromosomal region 1q31 that encodes CFH is a major susceptibility locus for AMD according to wholegenome association analyses performed independently in three different cohorts [45] [46] [47]. The CFHY402H allele (rs1061170, "
    [Show abstract] [Hide abstract] ABSTRACT: Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly, especially in Western countries. Although the prevalence, risk factors, and clinical course of the disease are well described, its pathogenesis is not entirely elucidated. AMD is associated with a variety of biochemical abnormalities, including complement components deposition in the retinal pigment epithelium-Bruch's membrane-choriocapillaris complex. Although the complement system (CS) is increasingly recognized as mediating important roles in retinal biology, its particular role in AMD pathogenesis has not been precisely defined. Unrestricted activation of the CS following injury may directly damage retinal tissue and recruit immune cells to the vicinity of active complement cascades, therefore detrimentally causing bystander damage to surrounding cells and tissues. On the other hand, recent evidence supports the notion that an active complement pathway is a necessity for the normal maintenance of the neurosensory retina. In this scenario, complement activation appears to have beneficial effect as it promotes cell survival and tissue remodeling by facilitating the rapid removal of dying cells and resulting cellular debris, thus demonstrating anti-inflammatory and neuroprotective activities. In this review, we discuss both the beneficial and detrimental roles of CS in degenerative retina, focusing on the diverse aspects of CS functions that may promote or inhibit macular disease.
    Full-text · Article · Sep 2014 · Research Journal of Immunology
    0Comments 8Citations
Show more

Similar publications

Discover cutting-edge research

ResearchGate is where you can find and access the latest publications from your field of research.

Discover more